COMPASS Pathways plc (CMPS)
COMPASS Pathways plc operates in the Biotechnology industry of the Healthcare sector, headquartered in London, CH, GB. The stock last traded at $14.14, up 5.68% on the session, giving a market capitalisation of $1.91B. On trailing twelve-month figures it carries a trailing P/E of -3.02, a net margin of 0.0%. Its beta of 2.52 implies it has historically moved more than the broad market.
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
COMPASS Pathways plc is most often compared with the following Healthcare names: